Exploring how patient biology could inform a drug asset? We’d be glad to hear from you. Read the PPMI white paper: www.biosymetrics.com/case-studies.... Visit BioSymetrics: www.biosymetrics.com. Visit Lunai Bioworks: www.lunaibioworks.com.
White Paper - Phenoclustering Parkinson's Disease to Uncover New Targets and Biomarkers — BioSymetrics
www.biosymetrics.com
October 2, 2026 at 3:07 PM
Exploring how patient biology could inform a drug asset? We’d be glad to hear from you. Read the PPMI white paper: www.biosymetrics.com/case-studies.... Visit BioSymetrics: www.biosymetrics.com. Visit Lunai Bioworks: www.lunaibioworks.com.
For Parkinson’s disease, BioSymetrics linked PPMI clinical and imaging features plus CSF proteomics (~4,500 probes) from 650+ participants to later outcomes, identifying 3 patterns.
October 2, 2026 at 3:07 PM
For Parkinson’s disease, BioSymetrics linked PPMI clinical and imaging features plus CSF proteomics (~4,500 probes) from 650+ participants to later outcomes, identifying 3 patterns.
BioSymetrics connects those profiles to biomarker hypotheses and uses the resulting biology to shape therapeutic hypotheses and development decisions. For a drug asset, this can inform patient selection, trial design, biomarker strategy, and target priorities.
October 2, 2026 at 3:07 PM
BioSymetrics connects those profiles to biomarker hypotheses and uses the resulting biology to shape therapeutic hypotheses and development decisions. For a drug asset, this can inform patient selection, trial design, biomarker strategy, and target priorities.
How can patient biology sharpen decisions in drug development? Our subsidiary, BioSymetrics, starts with longitudinal human data and machine learning to identify patient phenotypes. #ParkinsonsDisease #Biomarkers #DrugDiscovery
October 2, 2026 at 3:07 PM
How can patient biology sharpen decisions in drug development? Our subsidiary, BioSymetrics, starts with longitudinal human data and machine learning to identify patient phenotypes. #ParkinsonsDisease #Biomarkers #DrugDiscovery
Lunai Bioworks Licenses Tanaist’s Cellular Phenotyping Tech to Validate Parkinson’s Findings
Lunai Bioworks Licenses Tanaist’s Cellular Phenotyping Tech to Validate Parkinson’s Findings
The collaboration aims to link patient subtypes identified by BioSymetrics, Lunai's subsidiary, with cellular mechanisms.
ebx.sh
September 23, 2026 at 3:43 AM
Lunai Bioworks Licenses Tanaist’s Cellular Phenotyping Tech to Validate Parkinson’s Findings
Read the press release: ir.lunaibioworks.com/news/news-de.... Visit Lunai Bioworks: www.lunaibioworks.com. Learn more about BioSymetrics: www.biosymetrics.com.
Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement
Lunai Bioworks, Inc. (Nasdaq: LNAI), a biology-first AI drug discovery company, today announced an exclusive worldwide license and collaboration agreement with Tanaist, Inc. that adds human cellular p...
ir.lunaibioworks.com
September 22, 2026 at 4:33 PM
Read the press release: ir.lunaibioworks.com/news/news-de.... Visit Lunai Bioworks: www.lunaibioworks.com. Learn more about BioSymetrics: www.biosymetrics.com.
Through its subsidiary, BioSymetrics, Lunai Bioworks analyzed longitudinal clinical information and more than 4,500 proteomic probes from more than 650 Parkinson's Progression Markers Initiative participants, identifying three clinically distinct Parkinson's subtypes.
September 22, 2026 at 4:33 PM
Through its subsidiary, BioSymetrics, Lunai Bioworks analyzed longitudinal clinical information and more than 4,500 proteomic probes from more than 650 Parkinson's Progression Markers Initiative participants, identifying three clinically distinct Parkinson's subtypes.
Lunai Bioworks has announced an exclusive worldwide license and collaboration agreement with Tanaist, adding human cellular phenotyping to its AI-driven Parkinson's disease platform. #ParkinsonsDisease #CellularPhenotyping #ExperimentalValidation
September 22, 2026 at 4:33 PM
Lunai Bioworks has announced an exclusive worldwide license and collaboration agreement with Tanaist, adding human cellular phenotyping to its AI-driven Parkinson's disease platform. #ParkinsonsDisease #CellularPhenotyping #ExperimentalValidation
#LNAI Lunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AI
https://www.stocktitan.net/news/LNAI/lunai-bioworks-nasdaq-lnai-demonstrates-ai-chemical-risk-screening-nmfhzfrn5idu.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/LNAI/lunai-bioworks-nasdaq-lnai-demonstrates-ai-chemical-risk-screening-nmfhzfrn5idu.html?utm_source=stocktitan-bluesky&utm_medium=social
Lunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AI
Lunai Bioworks (LNAI) reported a BioSymetrics case study showing AI-based screening of chemical structures for acetylcholinesterase (AChE) inhibition, aimed at supporting chemical-risk controls for generative AI outputs.Using NIH Tox21 AChE assay data on 9,667 compounds, the selected model achieved an AUROC of 0.88 and 33% precision at 70% recall, corresponding to about 5.1-fold enrichment over the dataset’s 6.4% prevalence of AChE‑active entries. The structure-based screen is designed to operate independently of any specific large language model or molecular-generation system and to act as a downstream layer that prioritizes molecules for further computational, expert, or biological review.The work extends a multi-year, revenue-generating defense collaboration that links mechanism-of-action modeling with in vivo zebrafish phenotypic screening, and underpins more than US$30 million in submitted, but not yet awarded, non-dilutive grant applications in chemical defense and biosecurity.
www.stocktitan.net
September 16, 2026 at 1:25 PM
#LNAI Lunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AI
https://www.stocktitan.net/news/LNAI/lunai-bioworks-nasdaq-lnai-demonstrates-ai-chemical-risk-screening-nmfhzfrn5idu.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/LNAI/lunai-bioworks-nasdaq-lnai-demonstrates-ai-chemical-risk-screening-nmfhzfrn5idu.html?utm_source=stocktitan-bluesky&utm_medium=social
Learn more about BioSymetrics' clinical insights platform: www.biosymetrics.com. Visit Lunai Bioworks: www.lunaibioworks.com.
BioSymetrics - Phenomics-Driven. Remote-First.
BioSymetrics is a phenomics-driven drug discovery company that integrates clinical and experimental data, using machine learning, to translate human disease biology and advance precision medicine. We ...
www.biosymetrics.com
September 10, 2026 at 5:10 PM
Learn more about BioSymetrics' clinical insights platform: www.biosymetrics.com. Visit Lunai Bioworks: www.lunaibioworks.com.
CDD research needs scalable, disease-relevant models. The collaboration combines BioSymetrics' clinical insights platform with CRISPR/Cas9 cdkl5-deficient zebrafish for neurological phenotyping and human CDKL5 patient-derived brain organoids for translational validation.
September 10, 2026 at 5:10 PM
CDD research needs scalable, disease-relevant models. The collaboration combines BioSymetrics' clinical insights platform with CRISPR/Cas9 cdkl5-deficient zebrafish for neurological phenotyping and human CDKL5 patient-derived brain organoids for translational validation.
Our subsidiary, BioSymetrics, has initiated a collaboration focused on CDKL5 Deficiency Disorder (CDD), a rare genetic epilepsy. It is working with BrainStorm Therapeutics and academic collaborators to discover and validate therapeutic candidates. #CDKL5 #RareEpilepsy #DrugDiscovery
September 10, 2026 at 5:10 PM
Our subsidiary, BioSymetrics, has initiated a collaboration focused on CDKL5 Deficiency Disorder (CDD), a rare genetic epilepsy. It is working with BrainStorm Therapeutics and academic collaborators to discover and validate therapeutic candidates. #CDKL5 #RareEpilepsy #DrugDiscovery
Explore the BioSymetrics website: www.biosymetrics.com. Visit the Lunai Bioworks website: www.lunaibioworks.com. Request a copy of the Parkinson's disease white paper: www.biosymetrics.com/case-studies....
BioSymetrics - Phenomics-Driven. Remote-First.
BioSymetrics is a phenomics-driven drug discovery company that integrates clinical and experimental data, using machine learning, to translate human disease biology and advance precision medicine. We ...
www.biosymetrics.com
August 27, 2026 at 5:24 PM
Explore the BioSymetrics website: www.biosymetrics.com. Visit the Lunai Bioworks website: www.lunaibioworks.com. Request a copy of the Parkinson's disease white paper: www.biosymetrics.com/case-studies....
BioSymetrics (a Lunai Bioworks company) reported three outcome-linked subtypes in Parkinson's disease research: fast motor progression, cognitive and neurological decline, and a female-enriched group with broad functional impact.
August 27, 2026 at 5:24 PM
BioSymetrics (a Lunai Bioworks company) reported three outcome-linked subtypes in Parkinson's disease research: fast motor progression, cognitive and neurological decline, and a female-enriched group with broad functional impact.
Parkinson's disease and Alzheimer's disease may each include different forms with distinct symptoms, progression, and treatment response. Earlier, more precise diagnostics require understanding each patient's biology. #PrecisionNeurology #Neurodegeneration #Biomarkers
August 27, 2026 at 5:24 PM
Parkinson's disease and Alzheimer's disease may each include different forms with distinct symptoms, progression, and treatment response. Earlier, more precise diagnostics require understanding each patient's biology. #PrecisionNeurology #Neurodegeneration #Biomarkers
Request the white paper: www.biosymetrics.com/case-studies...
White Paper - Phenoclustering Parkinson's Disease to Uncover New Targets and Biomarkers — BioSymetrics
www.biosymetrics.com
August 19, 2026 at 6:04 PM
Request the white paper: www.biosymetrics.com/case-studies...
We are highlighting a white paper from BioSymetrics (a Lunai Bioworks company) on Parkinson's disease, released earlier this month. It explores how phenoclustering can help make sense of patient variation. #ParkinsonsDisease #PrecisionMedicine #Phenoclustering
August 19, 2026 at 6:04 PM
We are highlighting a white paper from BioSymetrics (a Lunai Bioworks company) on Parkinson's disease, released earlier this month. It explores how phenoclustering can help make sense of patient variation. #ParkinsonsDisease #PrecisionMedicine #Phenoclustering
BioSymetrics worked with Dr. Calum MacRae and his team at Brigham and Women’s Hospital to develop the in vivo phenomics platform. Learn more: www.biosymetrics.com.
BioSymetrics - Phenomics-Driven. Remote-First.
BioSymetrics is a phenomics-driven drug discovery company that integrates clinical and experimental data, using machine learning, to translate human disease biology and advance precision medicine. We ...
www.biosymetrics.com
August 14, 2026 at 3:54 PM
BioSymetrics worked with Dr. Calum MacRae and his team at Brigham and Women’s Hospital to develop the in vivo phenomics platform. Learn more: www.biosymetrics.com.
Rather than rely on a single behavioral assay, BioSymetrics built a scalable in vivo phenomics platform that measures multiple dimensions of disease biology at once.
August 14, 2026 at 3:54 PM
Rather than rely on a single behavioral assay, BioSymetrics built a scalable in vivo phenomics platform that measures multiple dimensions of disease biology at once.
BioSymetrics (a Lunai Bioworks company) has completed Phase I of its NIH-funded Fast-Track STTR program, which explored whether AI can help discover better treatments for Alcohol Use Disorder. #AlcoholUseDisorder #DrugDiscovery #PreclinicalResearch
August 14, 2026 at 3:54 PM
BioSymetrics (a Lunai Bioworks company) has completed Phase I of its NIH-funded Fast-Track STTR program, which explored whether AI can help discover better treatments for Alcohol Use Disorder. #AlcoholUseDisorder #DrugDiscovery #PreclinicalResearch
Request the Parkinson’s disease white paper: www.biosymetrics.com/case-studies.... Visit BioSymetrics: www.biosymetrics.com. Visit Lunai Bioworks: www.lunaibioworks.com.
White Paper - Phenoclustering Parkinson's Disease to Uncover New Targets and Biomarkers — BioSymetrics
www.biosymetrics.com
August 4, 2026 at 7:42 PM
Request the Parkinson’s disease white paper: www.biosymetrics.com/case-studies.... Visit BioSymetrics: www.biosymetrics.com. Visit Lunai Bioworks: www.lunaibioworks.com.
BioSymetrics’ Contingent AI™ platform and BrainStorm’s organoid and AI capabilities connect patient subtypes with biological mechanisms, biomarkers, and therapeutic targets. A new white paper describes the PPMI analysis and its clinically distinct Parkinson’s disease subtypes.
August 4, 2026 at 7:42 PM
BioSymetrics’ Contingent AI™ platform and BrainStorm’s organoid and AI capabilities connect patient subtypes with biological mechanisms, biomarkers, and therapeutic targets. A new white paper describes the PPMI analysis and its clinically distinct Parkinson’s disease subtypes.
Lunai Bioworks and BrainStorm Therapeutics signed a Master Collaboration Agreement. The work combines AI-driven Parkinson’s disease patient stratification with patient-derived midbrain organoids. #ParkinsonsDisease #PrecisionNeuroscience #DrugDiscovery
August 4, 2026 at 7:42 PM
Lunai Bioworks and BrainStorm Therapeutics signed a Master Collaboration Agreement. The work combines AI-driven Parkinson’s disease patient stratification with patient-derived midbrain organoids. #ParkinsonsDisease #PrecisionNeuroscience #DrugDiscovery
The workflow connects human data, machine learning, and living-system experiments. It analyzes, predicts, validates, and refines. Learn more: www.biosymetrics.com. Explore Lunai Bioworks: www.lunaibioworks.com.
BioSymetrics - Phenomics-Driven. Remote-First.
BioSymetrics is a phenomics-driven drug discovery company that integrates clinical and experimental data, using machine learning, to translate human disease biology and advance precision medicine. We ...
www.biosymetrics.com
July 23, 2026 at 6:36 PM
The workflow connects human data, machine learning, and living-system experiments. It analyzes, predicts, validates, and refines. Learn more: www.biosymetrics.com. Explore Lunai Bioworks: www.lunaibioworks.com.
BioSymetrics’ Contingent AI searches combinations of analytical choices around the question being asked. It finds reproducible, interpretable signals using patent-protected methods for pipeline optimization, feature selection, and model tuning.
July 23, 2026 at 6:36 PM
BioSymetrics’ Contingent AI searches combinations of analytical choices around the question being asked. It finds reproducible, interpretable signals using patent-protected methods for pipeline optimization, feature selection, and model tuning.